Bottom line
IBB vs FBTAX: the short answer
IBB (iShares Biotechnology ETF) and FBTAX (Fidelity Advisor Biotechnology Fund) are quite different portfolios: only about 31% of their top holdings (by weight) are shared.
IBB is cheaper at 0.44% vs 0.94% — a difference of $50 a year per $10,000 invested.
Over five years, FBTAX returned +6.4% a year vs +2.5% for IBB (reporting dates differ).
Updated Nov 19, 2026
IBB vs FBTAX side by side
| IBB | FBTAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Fidelity |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.44% | 0.94% |
| Annual cost per $10k | $44 | $94 |
| 10-yr cost on $10k (prospectus) | $555 | $1,663 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +28.0% | +31.5% |
| 5-yr return (annualized) | +2.5% | +6.4% |
| 10-yr return (annualized) | +4.4% | +7.7% |
| Best quarter | +26.8% | +30.3% |
| Worst quarter | −22.9% | −27.8% |
| Net assets (fund) | $5.9B | $2.2B |
| Number of holdings | 254 | 129 |
| Portfolio turnover | 27% | 54% |
| Returns as of | Dec 31, 2025 | Sep 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBB | FBTAX | Difference |
|---|---|---|---|
| 2025 | +28.0% | +39.6% | −11.5% |
| 2024 | −2.4% | +5.3% | −7.7% |
| 2023 | +3.6% | +10.7% | −7.1% |
| 2022 | −13.6% | −8.0% | −5.6% |
| 2021 | +1.0% | −3.6% | +4.6% |
| 2020 | +25.9% | +32.2% | −6.3% |
| 2019 | +24.8% | +25.7% | −1.0% |
| 2018 | −9.1% | −3.8% | −5.4% |
| 2017 | +21.2% | +25.8% | −4.6% |
| 2016 | −21.5% | −23.6% | +2.1% |
Source: Fund prospectus bar charts
Holdings overlap
9 of IBB's top 25 holdings also appear in FBTAX's top 25.
| Holding | IBB | FBTAX |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 7.66% | 1.39% |
| Gilead Sciences, Inc. | 7.52% | 5.70% |
| Amgen, Inc. | 7.50% | 2.37% |
| Alnylam Pharmaceuticals, Inc. | 5.68% | 3.62% |
| Argenx SE | 3.15% | 3.00% |
| Insmed, Inc. | 2.95% | 3.05% |
| Natera, Inc. | 2.11% | 1.43% |
| Biogen, Inc. | 2.03% | 2.71% |
| Moderna, Inc. | 0.88% | 1.60% |
Source: SEC Form N-PORT
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
FBTAX top 10
- Abbvie Inc — 14.71%
- Gilead Sciences Inc — 5.70%
- Spyre Therapeutics Inc — 3.83%
- Alnylam Pharmaceuticals Inc — 3.62%
- Dianthus Therapeutics Inc — 3.55%
- Cogent Biosciences Inc — 3.25%
- Oruka Therapeutics Inc — 3.24%
- Insmed Inc — 3.05%
- Revolution Medicines Inc — 3.00%
- Argenx Se — 3.00%
FAQ
What is the difference between IBB and FBTAX?
Which is cheaper, IBB or FBTAX?
Should I own both IBB and FBTAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.